CYTK
Cytokinetics Inc
NASDAQ: CYTK · HEALTHCARE · BIOTECHNOLOGY
$76.91
+3.53% today
Updated 2026-05-08
Market cap
$9.31B
P/E ratio
—
P/S ratio
105.78x
EPS (TTM)
$-6.54
Dividend yield
—
52W range
$29 – $80
Volume
2.5M
WallStSmart proprietary scores
24
out of 100
Grade: F
Strong Sell
Investment rating
3.3
Growth
D5.8
Quality
C+2.5
Profitability
F4.0
Valuation
C5/9
Piotroski F-Score
Moderate
-3.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →195 stocks currently score above 75
Price targets
Analyst target
$96.05
+24.89%
12-Month target
—
—
Intrinsic (DCF)
$56.52
Margin of safety
-18.19%
7 Strong Buy11 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Altman Z -3.69 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-151.39M
- 18.19% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $94.59M | $7.53M | $18.47M | $88.04M | $88.04M |
| Net income | $-388.95M | $-526.24M | $-589.53M | $-784.96M | $-206.03M |
| EPS | — | — | — | — | $-6.54 |
| Free cash flow | $-310.85M | $-415.75M | $-399.80M | $-534.82M | $-151.39M |
| Profit margin | -411.21% | -6,988.63% | -3,191.11% | -891.60% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-30 | CALLOS, ANDREW | Sale | 15,000 | — |
| 2026-04-30 | CALLOS, ANDREW | Buy | 15,000 | $23.26 |
| 2026-04-29 | BLUM, ROBERT I | Sale | 7,500 | $59.62 |
Peer comparison
Smart narrative
Cytokinetics Inc trades at $76.91. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -3.69, it sits in the distress. TTM revenue stands at $88.04M. Our DCF model estimates intrinsic value at $56.52.
Frequently asked questions
What is Cytokinetics Inc's stock price?
Cytokinetics Inc (CYTK) trades at $76.91.
Is Cytokinetics Inc overvalued?
Smart Value Score 24/100 (Grade F, Strong Sell). DCF value $56.52.
What is the price target of Cytokinetics Inc (CYTK)?
The analyst target price is $96.05, representing +24.9% upside from the current price of $76.91.
What is the intrinsic value of Cytokinetics Inc (CYTK)?
Based on our DCF model, intrinsic value is $56.52, a -18.2% margin of safety versus $76.91.
What is Cytokinetics Inc's revenue?
TTM revenue is $88.04M.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
-3.69 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio105.78x
ROE-572.00%
Beta0.38
50D MA$63.98
200D MA$58.16
Shares out0.12B
Float0.12B
Short ratio—
Avg volume2.5M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—